FAB — Fusion Antibodies Balance Sheet
0.000.00%
- £7.71m
- £7.30m
- £1.14m
Annual balance sheet for Fusion Antibodies, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 1.54 | 2.69 | 2.05 | 0.195 | 1.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.628 | 0.781 | 1.02 | 0.695 | 0.491 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 2.8 | 4.71 | 4.28 | 1.69 | 2.26 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.47 | 1.12 | 0.633 | 0.375 | 0.158 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 6.04 | 5.83 | 4.92 | 2.06 | 2.42 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.989 | 0.996 | 1.21 | 0.879 | 0.584 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 1.23 | 1.08 | 1.23 | 0.939 | 0.627 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 4.81 | 4.75 | 3.68 | 1.12 | 1.79 |
Total Liabilities & Shareholders' Equity | 6.04 | 5.83 | 4.92 | 2.06 | 2.42 |
Total Common Shares Outstanding |